Loading...

Search Results (829)

MatchTypeWhy
Cancer-associated fibroblasts derived from EGFR-TKI-resistant tumors reverse EGFR pathway inhibition by EGFR-TKIs.Academic Article Why?
Genetic Modifiers such as Fas Regulate Tumor-Cell Dependence on Mutant EGFRGrant Why?
Grandis, JenniferPerson Why?
Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain.Academic Article Why?
Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.Academic Article Why?
Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.Academic Article Why?
Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells.Academic Article Why?
Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors.Academic Article Why?
A urokinase receptor-Bim signaling axis emerges during EGFR inhibitor resistance in mutant EGFR glioblastoma.Academic Article Why?
Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab.Academic Article Why?
Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC.Academic Article Why?
DOK2 inhibits EGFR-mutated lung adenocarcinoma.Academic Article Why?
EGFR-mediated cell cycle regulation.Academic Article Why?
EGFR-targeted therapies in the post-genomic era.Academic Article Why?
EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition.Academic Article Why?
Per Page    Page  of 56 Next
Prev
Search Criteria
  • EGFR
Search Result Filters